Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer
- DOI
- 10.1007/s40259-026-00800-1
- Published
- 2026-08-02
- Container
- BioDrugs
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s40259-026-00800-1,
title = {Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer},
author = {Taekyung Kim and Heungjo Kim and Hongjae Lee and Keumyoung Ahn and Taehong Park and Hyungseok Baek and Min Jung Chang},
year = {2026},
journal = {BioDrugs},
doi = {10.1007/s40259-026-00800-1},
url = {https://doi.org/10.1007/s40259-026-00800-1}
}RIS
TY - JOUR TI - Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer AU - Taekyung Kim AU - Heungjo Kim AU - Hongjae Lee AU - Keumyoung Ahn AU - Taehong Park AU - Hyungseok Baek AU - Min Jung Chang PY - 2026 JO - BioDrugs DO - 10.1007/s40259-026-00800-1 UR - https://doi.org/10.1007/s40259-026-00800-1 ER -
APA
Kim, T., Kim, H., Lee, H., Ahn, K., Park, T., Baek, H., & Chang, M. J. (2026). Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer. BioDrugs. https://doi.org/10.1007/s40259-026-00800-1
Source records
- crossref · retrieved 2026-11-10T11:04:43.537Z